Core Insights - Rapport Therapeutics announced positive results from the PET and MAD-2 trials for RAP-219, demonstrating its potential for treating focal epilepsy and confirming its dosing regimen for the ongoing Phase 2a trial [1][2][3] Trial Results - In the PET trial, RAP-219 achieved target receptor occupancy (RO) associated with maximal efficacy within five days of dosing, exceeding the target range of 50%-70% [10] - The MAD-2 trial showed RAP-219 was generally well tolerated, with no serious adverse events and no treatment emergent adverse events greater than Grade 2 [2][11] - The trials confirmed the neuroanatomical specificity of RAP-219 through selective targeting of TARP8, which is enriched in the hippocampus and cerebral cortex [8][10] Dosing and Tolerability - The ongoing Phase 2a trial is on track, with topline data expected in mid-2025, and the dosing regimen has been supported by the trial results [1][3][7] - RAP-219 demonstrated favorable tolerability across various dosing regimens, with a long half-life of 8-14 days and minimal drug-drug interactions, making it suitable for polypharmacy [8][12] Company Overview - Rapport Therapeutics is focused on developing small molecule precision medicines for CNS disorders, leveraging its RAP technology platform to create differentiated product candidates [9] - The company is advancing RAP-219 as a treatment for focal epilepsy, diabetic peripheral neuropathic pain, and bipolar mania, with additional programs targeting chronic pain and hearing disorders [12]
Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders